A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies

NCT07735533 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

274

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma, B Cell
Lymphoma Non-Hodgkin
High Grade B Cell Lymphoma
Richter Transformation Lymphoma
Grade 3b Follicular Lymphoma
Primary Mediastinal B Cell Lymphoma
Diffuse Large B Cell Lymphoma (DLBCL)

Interventions

GENETIC: UB-VV400
DRUG: Rapamycin (sirolimus)

Sponsor

Umoja Biopharma